We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has ordered Pfizer to withdraw an advertisement for Zyvox, an antibiotic used to treat certain types of serious infection.
Shionogi and BioCryst Pharmaceuticals announced they have entered into an exclusive license agreement to develop and commercialize BioCryst's lead neuraminidase inhibitor, peramivir, for the treatment of influenza in Japan.
New data presented by Médecins Sans Frontières (MSF) at last week's Conference on Retroviruses and Opportunistic Infections demonstrates good clinical outcomes for second-line antiretroviral (ARV) therapy in resource-poor settings.
The FDA issued a final guidance giving recommendations on how to design, conduct and evaluate clinical studies looking at the effects of corticosteroids on growth in children.
Less than three years after first establishing its European headquarters in London, Eisai announced it has established a European pharmaceutical manufacturing subsidiary, Eisai Manufacturing.
China's diabetes research sector got a boost this week when Novo Nordisk and the Chinese Academy of Science (CAS) announced they signed an agreement to establish a joint research foundation.
Strides Arcolab has received tentative approval from the U.S. FDA for its HIV drug regimen consisting of lamivudine/zidovudine 150-mg/300-mg tablets co-packaged with nevirapine 200-mg tablets.
Canadian drugmaker Biovail has announced it has reached a comprehensive settlement with Anchen Pharmaceuticals, Impax Laboratories, Watson Pharmaceuticals and Teva Pharmaceutical Industries related to Wellbutrin XL.
Idenix Pharmaceuticals announced that Sebvio has received approval from the Chinese State Food and Drug Administration as a once-a-day treatment for chronic hepatitis B.